Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 1/2017

01-01-2017 | Original Paper

K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth

Authors: Efterpi Dalpa, Victor Gourvas, Nikolaos Soulitzis, Demetrios A. Spandidos

Published in: Medical Oncology | Issue 1/2017

Login to get access

Abstract

Nephroblastoma (Wilms tumor) is a kidney neoplasia, predominately occurring at very young age, resulting from the malignant transformation of renal stem cells. The Ras proto-oncogenes and B-Raf are members of an intracellular cascade pathway, which regulates cell growth and differentiation, and ultimately cancer development. Our objective was to determine the mutation rate and to measure the mRNA levels of the three Ras genes and of B-Raf in formalin-fixed paraffin-embedded tissue samples from 32 patients with nephroblastoma and 10 controls. No mutations were detected in the four studied genes among our Wilms tumors cases, while Ras and B-Raf expression was higher in malignant samples versus controls. Statistical analysis revealed a positive correlation of K-Ras (p < 0.001) and B-Raf (p = 0.006) with tumor size, a negative correlation of K-Ras (p = 0.041) and H-Ras (p = 0.033) with the percentage of tissue necrosis, and an association of N-Ras (p = 0.047) and B-Raf (p = 0.044) with tissue histology. From the above, we deduce that although Ras and B-Raf mutations are rare events in Wilms tumors, their expression pattern suggests that they play an important role in the development and progression of this malignancy.
Literature
1.
Breslow N, Olshan A, Beckwith JB, Green DM. Epidemiology of Wilms tumor. Med Pediatr Oncol. 1993;21:172–81.CrossRefPubMed
2.
van den Heuvel-Eibrink MM, Grundy P, Graf N, Pritchard-Jones K, Bergeron C, Patte C, et al. Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: a collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms Tumor Study Groups. Pediatr Blood Cancer. 2008;50:1130–4.CrossRefPubMed
3.
Coppes MJ, Arnold M, Beckwith JB, Ritchey ML, D’Angio GJ, Green DM, et al. Factors affecting the risk of contralateral Wilms tumor development: a report from the National Wilms Tumor Study Group. Cancer. 1999;85:1616–25.CrossRefPubMed
4.
Scott RH, Stiller CA, Walker L, Rahman N. Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genet. 2006;43:705–15.CrossRefPubMedPubMedCentral
5.
Coppes MJ, Haber DA, Grundy PE. Genetic events in the development of Wilms’ tumor. N Engl J Med. 1994;331:586–90.CrossRefPubMed
6.
Knudson AG Jr, Strong LC. Mutation and cancer: a model for Wilms’ tumor of the kidney. J Natl Cancer Inst. 1972;48:313–24.PubMed
7.
Satoh Y, Nakadate H, Nakagawachi T, Higashimoto K, Joh K, Masaki Z, et al. Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms’ tumours. Br J Cancer. 2006;95:541–7.CrossRefPubMedPubMedCentral
8.
Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science. 2007;315:642–5.CrossRefPubMed
9.
10.
Koesters R, Ridder R, Kopp-Schneider A, Betts D, Adams V, Niggli F, et al. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms’ tumors. Cancer Res. 1999;59:3880–2.PubMed
11.
Isidor B, Bourdeaut F, Lafon D, Plessis G, Lacaze E, Kannengiesser C, et al. Wilms’ tumor in patients with 9q22.3 microdeletion syndrome suggests a role for PTCH1 in nephroblastomas. Eur J Hum Genet. 2013;21:784–7.CrossRefPubMed
12.
Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005;23:7312–21.CrossRefPubMed
13.
14.
15.
Kiaris H, Spandidos D. Mutations of ras genes in human tumors (review). Int J Oncol. 1995;7:413–21.PubMed
16.
17.
Vageli D, Kiaris H, Delakas D, Anezinis P, Cranidis A, Spandidos DA. Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors. Cancer Lett. 1996;107:241–7.CrossRefPubMed
18.
Mammas IN, Zafiropoulos A, Koumantakis E, Sifakis S, Spandidos DA. Transcriptional activation of H- and N-ras oncogenes in human cervical cancer. Gynecol Oncol. 2004;92:941–8.CrossRefPubMed
19.
Lymbouridou R, Soufla G, Chatzinikola AM, Vakis A, Spandidos DA. Down-regulation of K-ras and H-ras in human brain gliomas. Eur J Cancer. 2009;45:1294–303.CrossRefPubMed
20.
Marais R, Marshall CJ. Control of the ERK MAP kinase cascade by Ras and Raf. Cancer Surv. 1996;27:101–25.PubMed
21.
Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol. 1997;9:180–6.CrossRefPubMed
22.
Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:855–67.CrossRefPubMed
23.
24.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.CrossRefPubMed
25.
Araujo PP, Marcello MA, Tincani AJ, Guilhen AC, Morari EC, Ward LS. mRNA BRAF expression helps to identify papillary thyroid carcinomas in thyroid nodules independently of the presence of BRAFV600E mutation. Pathol Res Pract. 2012;208:489–92.CrossRefPubMed
26.
Derdas SP, Soulitzis N, Balis V, Sakorafas GH, Spandidos DA. Expression analysis of B-Raf oncogene in V600E-negative benign and malignant tumors of the thyroid gland: correlation with late disease onset. Med Oncol. 2013;30:336.CrossRefPubMed
27.
Luo XN, Reddy JC, Yeyati PL, Idris AH, Hosono S, Haber DA, et al. The tumor suppressor gene WT1 inhibits ras-mediated transformation. Oncogene. 1995;11:743–50.PubMed
28.
Vicent S, Chen R, Sayles LC, Lin C, Walker RG, Gillespie AK, et al. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest. 2010;120:3940–52.CrossRefPubMedPubMedCentral
29.
Wu C, Wang S, Xu C, Tyler A, Li X, Andersson C, et al. WT1 enhances proliferation and impedes apoptosis in KRAS mutant NSCLC via targeting cMyc. Cell Physiol Biochem. 2015;35:647–62.CrossRefPubMed
30.
Clark PE, Polosukhina D, Love H, Correa H, Coffin C, Perlman EJ, et al. beta-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms’ tumors. Am J Pathol. 2011;179:3045–55.CrossRefPubMedPubMedCentral
31.
Breslow NE, Beckwith JB, Perlman EJ, Reeve AE. Age distributions, birth weights, nephrogenic rests, and heterogeneity in the pathogenesis of Wilms tumor. Pediatr Blood Cancer. 2006;47:260–7.CrossRefPubMedPubMedCentral
32.
Chu A, Heck JE, Ribeiro KB, Brennan P, Boffetta P, Buffler P, et al. Wilms’ tumour: a systematic review of risk factors and meta-analysis. Paediatr Perinat Epidemiol. 2010;24:449–69.CrossRefPubMed
33.
Beckwith JB. Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. Am J Med Genet. 1998;79:268–73.CrossRefPubMed
34.
Fukuzawa R, Reeve AE. Molecular pathology and epidemiology of nephrogenic rests and Wilms tumors. J Pediatr Hematol Oncol. 2007;29:589–94.CrossRefPubMed
35.
36.
Ruteshouser EC, Robinson SM, Huff V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosom Cancer. 2008;47:461–70.CrossRefPubMedPubMedCentral
37.
Moulton T, Crenshaw T, Hao Y, Moosikasuwan J, Lin N, Dembitzer F, et al. Epigenetic lesions at the H19 locus in Wilms’ tumour patients. Nat Genet. 1994;7:440–7.CrossRefPubMed
38.
Steenman MJ, Rainier S, Dobry CJ, Grundy P, Horon IL, Feinberg AP. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms’ tumour. Nat Genet. 1994;7:433–9.CrossRefPubMed
39.
Ravenel JD, Broman KW, Perlman EJ, Niemitz EL, Jayawardena TM, Bell DW, et al. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst. 2001;93:1698–703.CrossRefPubMed
40.
Baird P, Wadey R, Cowell J. Loss of heterozygosity for chromosome region 11p15 in Wilms’ tumours is not related to HRAS gene transforming mutations. Oncogene. 1991;6:1147–9.PubMed
41.
Waber PG, Chen J, Nisen PD. Infrequency of ras, p53, WT1, or RB gene alterations in Wilms tumors. Cancer. 1993;72:3732–8.CrossRefPubMed
42.
Miao J, Kusafuka T, Fukuzawa M. Hotspot mutations of BRAF gene are not associated with pediatric solid neoplasms. Oncol Rep. 2004;12:1269–72.PubMed
43.
Zirn B, Samans B, Wittmann S, Pietsch T, Leuschner I, Graf N, et al. Target genes of the WNT/beta-catenin pathway in Wilms tumors. Genes Chromosom Cancer. 2006;45:565–74.CrossRefPubMed
44.
Kumar S, Hand PH, Marsden HB, Kumar P, Thor A. Quantitation of enhanced expression of ras-oncogene product (p21) in childhood renal tumours. Anticancer Res. 1991;11:1657–62.PubMed
45.
Aoki I, Yanoma S, Misugi K, Sasaki Y, Kikyo S. Ras p21 expression in nephroblastoma group tumors. Acta Pathol Jpn. 1987;37:1903–7.PubMed
46.
Rowe DH, Huang J, Kayton ML, Thompson R, Troxel A, O’Toole KM, et al. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms’ tumor. J Pediatr Surg. 2000;35:30–2.CrossRefPubMed
47.
Celiker MY, Wang M, Atsidaftos E, Liu X, Liu YE, Jiang Y, et al. Inhibition of Wilms’ tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA. Oncogene. 2001;20:4337–43.CrossRefPubMed
48.
Yokoi A, McCrudden KW, Huang J, Kim ES, Soffer SZ, Frischer JS, et al. Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu-expressing experimental Wilms’ tumor. J Pediatr Surg. 2003;38:1569–73.CrossRefPubMed
49.
Mackenzie GG, Bartels LE, Xie G, Papayannis I, Alston N, Vrankova K, et al. A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice. Neoplasia. 2013;15:1184–95.CrossRefPubMedPubMedCentral
50.
Khodayari N, Mohammed KA, Goldberg EP, Nasreen N. EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene. Cancer Gene Ther. 2011;18:806–16.CrossRefPubMed
51.
Charette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I, Starkel P. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Mol Cancer. 2010;9:256.CrossRefPubMedPubMedCentral
52.
Deng M, Tang H, Zhou Y, Zhou M, Xiong W, Zheng Y, et al. miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. J Cell Sci. 2011;124:2997–3005.CrossRefPubMed
53.
Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, et al. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther. 2011;10:336–46.CrossRefPubMedPubMedCentral
54.
Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J, et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res. 2006;66:999–1006.CrossRefPubMed
55.
Chiappetta G, Basile A, Arra C, Califano D, Pasquinelli R, Barbieri A, et al. BAG3 down-modulation reduces anaplastic thyroid tumor growth by enhancing proteasome-mediated degradation of BRAF protein. J Clin Endocrinol Metab. 2012;97:E115–20.CrossRefPubMed
56.
Peretz D, Kimel N, Fujii DK, Neufeld G. Overexpression of basic fibroblast growth factor complementary DNA in Ha-ras-transformed cells correlates with a decreased incidence of tumor necrosis. Cancer Res. 1993;53:158–64.PubMed
57.
Arends MJ, McGregor AH, Wyllie AH. Apoptosis is inversely related to necrosis and determines net growth in tumors bearing constitutively expressed myc, ras, and HPV oncogenes. Am J Pathol. 1994;144:1045–57.PubMedPubMedCentral
58.
Spandidos DA, Sourvinos G, Tsatsanis C, Zafiropoulos A. Normal ras genes: their onco-suppressor and pro-apoptotic functions (review). Int J Oncol. 2002;21:237–41.PubMed
59.
60.
Grabocka E, Pylayeva-Gupta Y, Jones MJ, Lubkov V, Yemanaberhan E, Taylor L, et al. Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell. 2014;25:243–56.CrossRefPubMedPubMedCentral
61.
Zhang Z, Wang Y, Vikis HG, Johnson L, Liu G, Li J, et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet. 2001;29:25–33.CrossRefPubMed
62.
Luo F, Poulogiannis G, Ye H, Hamoudi R, Dong G, Zhang W, et al. Wild-type K-ras has a tumour suppressor effect on carcinogen-induced murine colorectal adenoma formation. Int J Exp Pathol. 2014;95:8–15.CrossRefPubMed
63.
Benet M, Dulman RY, Suzme R, de Miera EV, Vega ME, Nguyen T, et al. Wild type N-ras displays anti-malignant properties, in part by downregulating decorin. J Cell Physiol. 2012;227:2341–51.CrossRefPubMedPubMedCentral
64.
Mar VJ, Wong SQ, Li J, Scolyer RA, McLean C, Papenfuss AT, et al. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res. 2013;19:4589–98.CrossRefPubMed
Metadata
Title
K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth
Authors
Efterpi Dalpa
Victor Gourvas
Nikolaos Soulitzis
Demetrios A. Spandidos
Publication date
01-01-2017
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2017
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-016-0862-5

Other articles of this Issue 1/2017

Medical Oncology 1/2017 Go to the issue

Original Paper

Clinicopathological evaluation of Sox10 expression in diffuse-type gastric adenocarcinoma

Original Paper

Identification of reference genes and miRNAs for qRT-PCR in human esophageal squamous cell carcinoma

Letter to the Editor

Reply: “Patients treated with neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-years follow-up”

Original Paper

The impact of extended lymph node dissection versus neoadjuvant therapy with limited lymph node dissection on biochemical recurrence in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis

Letter to the Editor

Two misquotes, a letter to the editor regarding the article by Zhanzhan Xu et al.

Original Paper

Assessment of oxidative/nitrative modifications of plasma proteins, selected ROTEM parameters and kinetics of fibrinogen polymerization in patients with multiple myeloma at diagnosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits